Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Search
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Diabetes dog symptoms chronic disease management
Learn about the symptoms of canine diabetes and how to manage the disease.
Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Fight against COVID-19 pandemic
Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Ukraine Help: The heroes of Mainz-Finthen
Travis Kelley helps Olena and Wasyl flee from Ukraine. This is the record of a dramatic and emotional rescue operation.
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Zoonotic diseases things you should know
Zoonotic diseases can be transmitted between animals and humans. They are more common than you may think – and they are on the rise. Find out how this affects you.
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
Work life balance
It's important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
Anna Race
Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced